[go: up one dir, main page]

PE20040465A1 - Heteroariloxi-ariloxi-pirimidina-2,4,6-triona n-sustituida como inhibidores de metaloproteinasa - Google Patents

Heteroariloxi-ariloxi-pirimidina-2,4,6-triona n-sustituida como inhibidores de metaloproteinasa

Info

Publication number
PE20040465A1
PE20040465A1 PE2003000399A PE2003000399A PE20040465A1 PE 20040465 A1 PE20040465 A1 PE 20040465A1 PE 2003000399 A PE2003000399 A PE 2003000399A PE 2003000399 A PE2003000399 A PE 2003000399A PE 20040465 A1 PE20040465 A1 PE 20040465A1
Authority
PE
Peru
Prior art keywords
triona
pyrimidine
alkyl
substituted
iloxi
Prior art date
Application number
PE2003000399A
Other languages
English (en)
Inventor
Lilli Ann Wolf-Gouveia
Mark Carl Noe
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20040465A1 publication Critical patent/PE20040465A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE R1 ES H, (R2)2n+1-(C)n- O CICLOALQUILO(C3-C7) OPCIONALMENTE SUSTITUIDO CON HALO, ALQUILO(C1-C4), ALQUENILO(C1-C4), R3-, R3-O-, PERFLUOROALCOXI(C1-C4), ENTRE OTROS; n ES DE 1 A 5; R2 ES UN HALO, ALQUENILO(C1-C4), ALQUINILO(C1-C4), R3(C=O)-O-, ENTRE OTROS; X ES -O-, >C=O, -S-, >SO2, >S=O, >NR5, -CH2-, -CH2O-, ENTRE OTROS; A ES ARILO(C6-C10) O HETEROARILO(C1-C10) OPCIONALMENTE SUSTITUIDO CON HALOGENO, CN, OH, ALQUILO(C1-C4), PERFLUOROALQUILO(C1-C4) ENTRE OTROS; Y ES UN ENLACE -O-, -S-, >C=O, >SO2, >S=O, -CH2SO2-, ENTRE OTROS; B ES UN HETEROCICLILO(C1-C10) CON AL MENOS UN NITROGENO EL CUAL SE ENLAZA CON UN C DE G; G ES UN ALQUILO(C1-C6) QUE PUEDE ESTAR SUSTITUIDO CON 1 O 3 SUSTITUYENTES DE HALOGENO, CN, OH, -(C=O)-NH2, ENTRE OTROS, O ES R7-(CR8R9)p; DONDE p ES DE O A 4; R7 ES CICLOALQUILO(C3-C7), ARILO(C6-C10), HETEROARILO(C1-C10), ENTRE OTROS; R8 Y R9 SON H, ALQUILO(C1-C4) O FORMAR UN ANILLO CARBOCICLICO DE 3 A 8 MIEMBROS. SON COMPUESTOS PREFERIDOS: 5-(2-METOXIETIL)-5-[4-(1-PIRIDIN-3-IL-1H-INDAZOL-5-ILOXI)FENOXI]PIRIMIDINA-2,4,6-TRIONA, 5-{4-[1-(4-FLUOROFENIL)-1H-INDAZOL-5-ILOXI]FENOXI}-5-(2-METOXIETIL)PIRIMIDINA-2,4,6-TRIONA, 5-{4-[1-(6-CLOROPIRIDIN-3-IL)-1H-INDAZOL-5-ILOXI]FENOXI}-5-(2-METOXIETIL)PIRIMIDINA-2,4,6-TRIONA. TAMBIEN SE REFIERE A COMPOSICIONES FARMACEUTICAS. ESTOS COMPUESTOS SON INHIBIDORES DE METALOPROTEINASAS DE MATRIZ Y SON UTILES EN EL TRATAMIENTO DE INFLAMACION, CANCERES, TRANSTORNOS INMUNOLOGICOS.
PE2003000399A 2002-04-26 2003-04-22 Heteroariloxi-ariloxi-pirimidina-2,4,6-triona n-sustituida como inhibidores de metaloproteinasa PE20040465A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37597402P 2002-04-26 2002-04-26

Publications (1)

Publication Number Publication Date
PE20040465A1 true PE20040465A1 (es) 2004-07-24

Family

ID=29270739

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000399A PE20040465A1 (es) 2002-04-26 2003-04-22 Heteroariloxi-ariloxi-pirimidina-2,4,6-triona n-sustituida como inhibidores de metaloproteinasa

Country Status (15)

Country Link
US (1) US6919332B2 (es)
EP (1) EP1507535A1 (es)
JP (1) JP2005529889A (es)
AR (1) AR039660A1 (es)
AU (1) AU2003223012A1 (es)
BR (1) BR0309556A (es)
CA (1) CA2483500A1 (es)
DO (1) DOP2003000632A (es)
GT (1) GT200300098A (es)
MX (1) MXPA04010550A (es)
PA (1) PA8572101A1 (es)
PE (1) PE20040465A1 (es)
TW (1) TW200406407A (es)
UY (1) UY27775A1 (es)
WO (1) WO2003090751A1 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05006567A (es) 2002-12-20 2005-08-16 Glaxo Group Ltd Derivados de benzazepina para el tratamiento de trastornos neurologicos.
CA2568640C (en) 2004-06-04 2011-08-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
EP1831225A2 (en) 2004-11-19 2007-09-12 The Regents of the University of California Anti-inflammatory pyrazolopyrimidines
MX2008012928A (es) 2006-04-04 2009-03-06 Univ California Antagonistas de pi3-cinasa.
UY30892A1 (es) * 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
GB2467670B (en) 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
ES2647163T3 (es) 2008-01-04 2017-12-19 Intellikine, Inc. Derivados de isoquinolinona sustituidos con una purina útiles como inhibidores de la PI3K
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
EP2252293B1 (en) 2008-03-14 2018-06-27 Intellikine, LLC Kinase inhibitors and methods of use
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
AU2009268611B2 (en) 2008-07-08 2015-04-09 Intellikine, Llc Kinase inhibitors and methods of use
JP5731978B2 (ja) 2008-09-26 2015-06-10 インテリカイン， エルエルシー 複素環キナーゼ阻害剤
CA2740885C (en) 2008-10-16 2018-04-03 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
JP5789252B2 (ja) 2009-05-07 2015-10-07 インテリカイン， エルエルシー 複素環式化合物およびその使用
WO2011047384A2 (en) 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
US8604032B2 (en) 2010-05-21 2013-12-10 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
EP2637669A4 (en) 2010-11-10 2014-04-02 Infinity Pharmaceuticals Inc Heterocyclic compounds and their use
KR20180080358A (ko) 2011-01-10 2018-07-11 인피니티 파마슈티칼스, 인코포레이티드 이소퀴놀린온 및 이의 고체 형태의 제조 방법
CA2828483A1 (en) 2011-02-23 2012-11-01 Intellikine, Llc Combination of kinase inhibitors and uses thereof
US8969363B2 (en) 2011-07-19 2015-03-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2013012918A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
CN103998442B (zh) 2011-08-29 2016-09-14 无限药品股份有限公司 杂环化合物及其用途
WO2013077921A2 (en) 2011-09-02 2013-05-30 The Regents Of The University Of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
WO2014052669A1 (en) 2012-09-26 2014-04-03 The Regents Of The University Of California Modulation of ire1
DK2914296T4 (da) 2012-11-01 2022-01-03 Infinity Pharmaceuticals Inc Behandling af cancere under anvendelse af PI3-kinase-isoform-modulatorer
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
TWI652014B (zh) 2013-09-13 2019-03-01 美商艾佛艾姆希公司 雜環取代之雙環唑殺蟲劑
ES2900806T3 (es) 2013-10-04 2022-03-18 Infinity Pharmaceuticals Inc Compuestos heterocíclicos y usos de los mismos
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
SG10201808053XA (en) 2014-03-19 2018-10-30 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
BR112017019326B1 (pt) * 2015-03-12 2022-04-26 Fmc Corporation Composto, composição e método para controlar uma praga invertebrada
JP6980649B2 (ja) 2015-09-14 2021-12-15 インフィニティー ファーマシューティカルズ， インコーポレイテッド イソキノリノン誘導体の固体形態、それを製造する方法、それを含む組成物、及びそれを使用する方法
CA3008131C (en) 2015-12-14 2022-05-10 Fmc Corporation Heterocycle-substituted bicyclic azole pesticides
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA3028718A1 (en) 2016-06-24 2017-12-28 Infinity Pharmaceuticals, Inc. Combination therapies
CN110636846B (zh) 2017-05-17 2023-05-16 艾库斯生物科学有限公司 用于治疗癌症相关疾病的喹唑啉吡唑衍生物
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN117003754B (zh) * 2022-04-28 2025-07-25 腾讯科技（深圳）有限公司 吡咯并[2,3-d]嘧啶或吡唑并[3,4-d]嘧啶衍生物及其用途
WO2025149545A1 (en) * 2024-01-11 2025-07-17 F. Hoffmann-La Roche Ag Heteroarylphenyl ether derivatives

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
BR9810450A (pt) 1997-06-21 2000-09-05 Roche Diagnostics Gmbh Derivados de ácido barbitúrico com atividade antimetastática e antitumor
US6265578B1 (en) 1999-02-12 2001-07-24 Hoffmann-La Roche Inc. Pyrimidine-2,4,6-triones
HN2000000137A (es) * 1999-08-12 2001-02-02 Pfizer Prod Inc Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas
US6468686B1 (en) * 2000-01-24 2002-10-22 Graftech Inc. Fluid permeable flexible graphite fuel cell electrode with enhanced electrical and thermal conductivity
CZ20031069A3 (cs) * 2000-10-26 2004-05-12 Pfizeráproductsáinc Pyrimidin@@Ź@Ź@@trionové inhibitory metaloproteinasy
US6841671B2 (en) * 2000-10-26 2005-01-11 Pfizer Inc. Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
NI200300045A (es) * 2002-04-26 2005-07-08 Pfizer Prod Inc Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa.
EP1501834B1 (en) 2002-04-26 2005-09-07 Pfizer Products Inc. Triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase inhibitors
DE60302150D1 (en) * 2002-04-26 2005-12-08 Pfizer Prod Inc N-substituiete heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trion metalloproteinase inhibitoren

Also Published As

Publication number Publication date
US6919332B2 (en) 2005-07-19
DOP2003000632A (es) 2003-10-31
TW200406407A (en) 2004-05-01
AU2003223012A1 (en) 2003-11-10
US20030232849A1 (en) 2003-12-18
JP2005529889A (ja) 2005-10-06
WO2003090751A1 (en) 2003-11-06
MXPA04010550A (es) 2005-01-25
UY27775A1 (es) 2003-11-28
PA8572101A1 (es) 2003-12-10
EP1507535A1 (en) 2005-02-23
GT200300098A (es) 2004-05-18
BR0309556A (pt) 2005-02-09
CA2483500A1 (en) 2003-11-06
AR039660A1 (es) 2005-03-02

Similar Documents

Publication Publication Date Title
PE20040465A1 (es) Heteroariloxi-ariloxi-pirimidina-2,4,6-triona n-sustituida como inhibidores de metaloproteinasa
NO20053587L (no) 3-(3,5-diokso-4,5-dihydro-3H-(1,2,4)triazin-2-yl-)benzamidderivater som P2X7-inhibitorer for behandling av inflammatoriske sykdommer.
CY1114022T1 (el) Φαρμακα με δραση υποδοχεα ημ74α
PE20071136A1 (es) Derivados de anilina sustituida como antagonistas de la histamina h3
CY1110399T1 (el) Ρυθμιστες της τετραϋδροπυρανυλο κυκλοπεντυλο τετραϋδροπυριδοπυριδινης για την ενεργοτητα των υποδοχεων των χημειοκινων
ATE442847T1 (de) Benzimidazol-derivate als mek-hemmer
NO20075384L (no) Tiadiazolsubstituerte kumarinderivater og deres anvendelse som leukotrienbiosynteseinhibitorer.
PE20090895A1 (es) Derivados de triazol como inhibidores de la jak quinasa
PE20070808A1 (es) COMPUESTOS DERIVADOS DE ISOQUINOLINA COMO INHIBIDORES DE Rho-QUINASA
NO20063599L (no) Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
PE20100138A1 (es) Derivados de morfolino pirimidina usados en enfermedades relacionadas en mtor quinasa y/o pi3k
PE20040940A1 (es) Derivados de 3-cicloalquil-indol como inhibidores de la polimerasa del virus de hepatitis c
PE20061353A1 (es) Compuestos de sulfonamida-tiazolopiridina como activadores de glucocinasa
AR058719A1 (es) Derivados de isoxazol-4-il-oxadiazol
ATE162521T1 (de) 3-aminopiperidine derivate und verwandete stickstoff enthaltende heterocyclische verbindungen
PE20050867A1 (es) DERIVADOS DE PIPERAZINA COMO INHIBIDORES DE LA INTERACCION DE gp 120 CON CD4
CO5570660A2 (es) Indazolilpirrolotriazinas c-6 modificadas
PE20030601A1 (es) Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y transtornos relacionados
CY1109300T1 (el) Νεοι συντηγμενοι ετεροκυκλικοι δακτυλιοι και χρησεις αυτων
CY1105198T1 (el) Παραγωγα πιπepιδινης χρησιμα σαν ανταγωνιστες ccr5 για τη θepαπεια ιου ανθρωπινης ανοσοανεπαρκειας (hiv)
CY1110831T1 (el) Αντι-ιικα μεσα τυπου διαζαινδολο-δικαρβονυλο-πιπεραζινυλιου
PE20040864A1 (es) Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
CR8505A (es) Derivados de (3-oxo-3,4-dihidroquinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad
HUP0401886A2 (hu) Kemokin receptor aktivitás modulátorokként alkalmazható piperidinszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
BRPI0312882B8 (pt) derivados de pleuromutilina e composição farmacêutica

Legal Events

Date Code Title Description
FA Abandonment or withdrawal